Search

Your search keyword '"Tiu, Bruce C"' showing total 11 results
Start Over Author "Tiu, Bruce C"
11 results on '"Tiu, Bruce C"'

1. Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study

Author

Bikdeli, Behnood, Khairani, Candrika D., Krishnathasan, Darsiya, Bejjani, Antoine, Armero, Andre, Tristani, Anthony, Davies, Julia, Porio, Nicole, Assi, Ali A., Nauffal, Victor, Campia, Umberto, Almarzooq, Zaid, Wei, Eric, Achanta, Aditya, Jesudasen, Sirus J., Tiu, Bruce C., Merli, Geno J., Leiva, Orly, Fanikos, John, Sharma, Aditya, Vishnevsky, Alec, Hsia, Judith, Nehler, Mark R., Welker, James, Bonaca, Marc P., Carroll, Brett J., Lan, Zhou, Goldhaber, Samuel Z., and Piazza, Gregory

Published
2023
Full Text
View/download PDF

3. Patterns in utilization of health care services and medications among patients with cutaneous immune-related adverse events: A population-level cohort study

Author

Leung, Bonnie W., primary, Collier, Michael Ryan, additional, Tiu, Bruce C., additional, Wan, Guihong, additional, Nguyen, Nga, additional, Tang, Kimberly, additional, Zhang, Shijia, additional, Chen, Wenxin, additional, Chen, Steven T., additional, LeBoeuf, Nicole R., additional, and Semenov, Yevgeniy R., additional

Published
2023
Full Text
View/download PDF

5. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study

Author

Tiu, Bruce C, primary, Zubiri, Leyre, additional, Iheke, James, additional, Pahalyants, Vartan, additional, Theodosakis, Nicholas, additional, Ugwu-Dike, Pearl, additional, Seo, Jayhyun, additional, Tang, Kimberly, additional, Sise, Meghan E, additional, Sullivan, Ryan, additional, Naidoo, Jarushka, additional, Mooradian, Meghan J, additional, Semenov, Yevgeniy R, additional, and Reynolds, Kerry L, additional

Published
2022
Full Text
View/download PDF

7. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Therapy

Author

Tang, Kimberly, primary, Seo, Jayhyun, additional, Tiu, Bruce C., additional, Le, Thomas K., additional, Pahalyants, Vartan, additional, Raval, Neel S., additional, Ugwu-Dike, Pearl O., additional, Zubiri, Leyre, additional, Naranbhai, Vivek, additional, Carrington, Mary, additional, Gusev, Alexander, additional, Reynolds, Kerry L., additional, LeBoeuf, Nicole R., additional, Asgari, Maryam M., additional, Kwatra, Shawn G., additional, and Semenov, Yevgeniy R., additional

Published
2022
Full Text
View/download PDF

11. Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy.

Author

Tang K, Tiu BC, Wan G, Zhang S, Nguyen N, Leung B, Gusev A, Reynolds KL, Kwatra SG, and Semenov YR

Subjects
B7-H1 Antigen, Humans, Programmed Cell Death 1 Receptor, United States, Antineoplastic Agents, Immunological adverse effects, Autoimmune Diseases chemically induced, Autoimmune Diseases complications, Autoimmune Diseases drug therapy, Neoplasms complications
Abstract

Although indications for immune checkpoint inhibitors (ICIs) have dramatically increased in the past decade, ICIs have been associated with autoinflammatory immune-related adverse events, which can resemble autoimmune diseases (ADs). Little is known about the impact of baseline AD on mortality in cancer patients treated with ICIs. Here, we identified 17 497 patients with preexisting autoimmune diagnoses prior to treatment with antiprogrammed cell death receptor-1 or antiprogrammed cell death ligand-1 therapy and 17 497 matched controls through the TriNetX Diamond network of more than 200 million patients across the United States and Europe. Using a Cox proportional hazards model, we found that patients with history of AD were not at higher risk of mortality than non-AD patients (hazard ratio [HR] = 1.03, 95% confidence interval [CI] = 1 to 1.07; P = .05). Additionally, history of Hashimoto disease (HR = 0.75, 95% CI = 0.62 to 0.90; P = .002) and vitiligo (HR = 0.52, 95% CI = 0.34 to 0.81; P = .003) were statistically significantly associated with decreased mortality. This suggests that underlying AD need not be a contraindication to inclusion in clinical trials and administration of ICI for treatment of cancer., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results